BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND ARHGEF12, Q9NZN5, 23365, ENSG00000196914, KIAA0382, LARG, DKFZp686O2372, PRO2792
8 results:

  • 1. Cobra (
    Rayapati AM; Vemulapati B; Chanda C
    J Biosci; 2024; 49():. PubMed ID: 38516910
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Comparison of the clinical and prognosis risk factors between endoscopic resection and radical gastrectomy for early-stage gastric cancer.
    Dao Q; Chen K; Zhu L; Wang X; Chen M; Wang J; Wang Z
    World J Surg Oncol; 2023 May; 21(1):147. PubMed ID: 37173790
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Endogenous NO-releasing Carbon Nanodots for Tumor-specific Gas Therapy.
    Liu X; Liu Y; Thakor AS; Kevadiya BD; Cheng J; Chen M; Li Y; Xu Q; Wu Q; Wu Y; Zhang G
    Acta Biomater; 2021 Dec; 136():485-494. PubMed ID: 34601108
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Association of Damaging Variants in Genes With Increased cancer Risk Among Patients With Congenital Heart Disease.
    Morton SU; Shimamura A; Newburger PE; Opotowsky AR; Quiat D; Pereira AC; Jin SC; Gurvitz M; Brueckner M; Chung WK; Shen Y; Bernstein D; Gelb BD; Giardini A; Goldmuntz E; Kim RW; Lifton RP; Porter GA; Srivastava D; Tristani-Firouzi M; Newburger JW; Seidman JG; Seidman CE
    JAMA Cardiol; 2021 Apr; 6(4):457-462. PubMed ID: 33084842
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Mono-PEGylation of a Thermostable Arginine-Depleting Enzyme for the Treatment of lung cancer.
    Chung SF; Kim CF; Kwok SY; Tam SY; Chen YW; Chong HC; Leung SL; So PK; Wong KY; Leung YC; Lo WH
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545874
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Effective combination treatment of lung cancer cells by single vehicular delivery of siRNA and different anticancer drugs.
    Li J; Wang Y; Xue S; Sun J; Zhang W; Hu P; Ji L; Mao Z
    Int J Nanomedicine; 2016; 11():4609-4624. PubMed ID: 27695321
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy.
    Stone E; Chantranupong L; Gonzalez C; O'Neal J; Rani M; VanDenBerg C; Georgiou G
    J Control Release; 2012 Feb; 158(1):171-9. PubMed ID: 22001609
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses.
    Rodriguez PC; Quiceno DG; Zabaleta J; Ortiz B; Zea AH; Piazuelo MB; Delgado A; Correa P; Brayer J; Sotomayor EM; Antonia S; Ochoa JB; Ochoa AC
    Cancer Res; 2004 Aug; 64(16):5839-49. PubMed ID: 15313928
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.